Colonisation Efficacy of Oral Probiotic Fast Melt Powder
Launched by BLIS TECHNOLOGIES LIMITED · May 5, 2022
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
This is a double-blind, randomized controlled study with no cross over to evaluate the colonization efficacy of fast melt powders containing a commercially available probiotic bacterium Streptococcus salivarius K12.
Participants will be randomly assigned to one of the 2 groups consuming Fast Melt powder containing two different doses of Streptococcus salivarius K12 over a seven day period. Saliva samples will be collected at predetermined time points pre and post intervention. Colonization efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. In general good health 18 - 80 years of age.
- • 2. Practice good oral hygiene.
- Exclusion Criteria:
- • 1. Have a history of autoimmune disease or are immunocompromised.
- • 2. Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
- • 3. History of allergy (e.g. dairy).
About Blis Technologies Limited
Blis Technologies Limited is an innovative biotechnology company focused on the development and commercialization of advanced microbial therapies for a range of health applications. With a commitment to harnessing the power of beneficial bacteria, the company specializes in research and clinical trials aimed at enhancing oral and systemic health through its proprietary probiotic formulations. Leveraging cutting-edge technology and a strong scientific foundation, Blis Technologies Limited strives to improve patient outcomes and contribute to the growing field of microbiome research, positioning itself as a leader in the development of safe and effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dunedin, Otago, New Zealand
Patients applied
Trial Officials
John D Hale, PhD
Study Director
Blis Technologies Ltd, Dunedin, New Zealand
John R Tagg, PhD
Principal Investigator
Blis Technologies Ltd, Dunedin, New Zealand
Rohit Jain, PhD
Principal Investigator
Blis Technologies Ltd, Dunedin, New Zealand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials